The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
The complexity of p53 modulation: emerging patterns from divergent signals
Open accessAbstract
Functional inactivation of p53 by gene mutation and deletion, protein degradation, or viral oncogene binding renders a mammalian cell susceptible to oncogenic stimuli and environmental insults that promote growth deregulation and malignant progression. Although a variety of mechanisms have been proposed for how p53 protects cells against neoplastic transformation, it is becoming clear that p53 integrates signals from the cell’s internal and external environment to respond to inappropriate growth promoting or growth inhibiting conditions (for review, see Gottleib and Oren 1995; Ko and Prives 1996; Levine 1997). This ‘‘sensor’’ function of p53 makes it unusual in the tumor suppressor gene family. The list of stimuli that alter p53 activity is increasing and our understanding of the signal transduction pathways used to signal to p53 are starting to become elucidated. The predominant regulation of p53 occurs at the protein level. Mutations in p53 that affect its conformation typically increase its half-life, in part by inhibiting degradation by the ubiquitin complex (Maki et al. 1996; Haupt et al. 1997; Kubbutat et al. 1997; Midgley and Lane 1997), and the majority of human tumor mutations decrease the sequence-specific DNA binding and transcriptional activity of p53 protein (Cho et al. 1994). In unstressed cells, p53 appears to be present at low levels and exists in a latent, inactive form that requires modification to become active. The types of modification that p53 is subjected to seem to be stress-, speciesand celltype-specific. Levels and/or activity of p53 increase in response to DNA damaging agents (Maltzman and Czyzyk 1984; Kastan et al. 1991; Nelson and Kastan 1994), decreased oxygen (Graeber et al. 1994), oncogenic stimuli (Debbas and White 1993; Lowe and Ruley 1993; Hermeking and Eick 1994; Wanger et al. 1994; Serrano et al. 1997), cell adhesion (Nigro et al. 1997), altered ribonucleotide pools (Linke et al. 1996), and redox stress (Hainaut and Milner 1993a; Hupp et al. 1993). Although all of these stresses signal the activation of p53 protein, unique pathways appear to be utilized by the different stresses. Is p53 protein accumulation needed for p53 activation or are modifications necessary for p53 activation separable from the modifications required for p53 protein accumulation? Both the modifiers and the types of modification will be important to sort out to understand the relationship between accumulation and activation. Although the two appear to be separable (Chernov et al. 1998; Hupp et al. 1995), it is possible that both are essential for full tumor suppressor function. The importance of p53 and modifications that affect its functions are not limited to malignant disease. The activity of p53 can increase in normal tissues when undergoing pathophysiological changes that result in oxidative or redox stress, such as ischemia and reperfusion injury of the brain, heart, and other tissues. Thus both oxidative stress generated by hydrogen peroxide, as well as reducing stresses generated by the lack of oxygen, appear to be potent stimulators of p53 activity. In addition, the link between p53 function and the modulation of angiogenesis further implicates p53 pathways in the processes of wound healing (Antoniades et al. 1994) and ischemic injury responses (Banasiak and Haddad 1998). At present little is known about the pathways that control p53 activity in response to ischemia and reperfusion in normal tissues, and this area should be fertile ground for research in future years. In this review, we discuss what is known about how various stressors signal to p53 and the various mechanisms utilized to modulate p53 activity. Because of the focus on signaling to p53, we will not attempt to discuss the ‘‘downstream’’ physiologic effects of p53 activation such as cell-cycle perturbations or cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“Levels and/or activity of p53 increase in response to DNA damaging agents (Maltzman and Czyzyk 1984; Kastan et al. 1991; Nelson and Kastan 1994), decreased oxygen (Graeber et al. 1994), oncogenic stimuli (Debbas and White 1993; Lowe and Ruley 1993; Hermeking and Eick 1994; Wanger et al. 1994; Serrano et al. 1997 ), ce…”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Self-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 3×
“Mutations in p53 that affect its conformation typically increase its half-life, in part by inhibiting degradation by the ubiquitin complex (Maki et al. 1996; Haupt et al. 1997; Kubbutat et al. 1997; Midgley and Lane 1997), and the majority of human tumor mutations decrease the sequence-specific DNA binding and transcr…”
BackgroundMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 2×
“It had been known for some time that the Mdm2 protein could inhibit p53 function by binding to and inhibiting transactivation by p53 ( Momand et al. 1992; Oliner et al. 1993; Thut et al. 1997), but these recent studies demonstrated that Mdm2 binding also targets p53 for rapid proteosomal degradation.”
BackgroundKastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 1×
“It has been known for some time that induction of p53 by IR is suboptimal in cells that lack the expression of the ATM kinase (Kastan et al. 1992; Khanna and Lavin 1993).”
BackgroundSelf-citationAssociation of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Research works printed but not linked: 1
- Girinsky, 1995, Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents., Cancer Res., 55, 3726
Cited by
Items 101–156 of 156
Direct Interactions between HIF-1α and Mdm2 Modulate p53 Function
Chen, D., Li, M., Luo, J., & Gu, W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200694200 · Cited by 334
A role for p53 in base excision repair
Zhou, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.914 · Cited by 333
The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation
SOUSSI, T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06705.x · Cited by 332
REDOX regulation of early embryo development
Harvey, A. J., Kind, K. L., & Thompson, J. G. (2002) · Reproduction · doi:10.1530/rep.0.1230479 · Cited by 332
Zhang, W., Geiman, D. E., Shields, J. M., Dang, D. T., Mahatan, C. S., Kaestner, K. H., Biggs, J. R., Kraft, A. S., & Yang, V. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000062200 · Cited by 327
Hypoxia Links ATR and p53 through Replication Arrest
Hammond, E. M., Denko, N. C., Dorie, M. J., Abraham, R. T., & Giaccia, A. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1834-1843.2002 · Cited by 324
Self-citationDNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes
Costanzo, A., Merlo, P., Pediconi, N., Fulco, M., Sartorelli, V., Cole, P. A., Fontemaggi, G., Fanciulli, M., Schiltz, L., Blandino, G., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00431-8 · Cited by 319
Signal Transduction and Cellular Radiation Responses
Schmidt-Ullrich, R. K., Dent, P., Grant, S., Mikkelsen, R. B., & Valerie, K. (2000) · Radiation Research · doi:10.1667/0033-7587(2000)153[0245:stacrr]2.0.co;2 · Cited by 316
Mechanisms underlying hypoxia-induced neuronal apoptosis
Banasiak, K. J., Xia, Y., & Haddad, G. G. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00011-3 · Cited by 303
Shieh, S.-Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1815 · Cited by 300
ATM: Genome stability, neuronal development, and cancer cross paths
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)83007-4 · Cited by 299
A DNA Damage–Induced p53 Serine 392 Kinase Complex Contains CK2, hSpt16, and SSRP1
Keller, D. M., Zeng, X., Wang, Y., Zhang, Q. H., Kapoor, M., Shu, H., Goodman, R., Lozano, G., Zhao, Y., & Lu, H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00176-9 · Cited by 299
Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., & Appella, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9278 · Cited by 293
Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function
Korgaonkar, C., Hagen, J., Tompkins, V., Frazier, A. A., Allamargot, C., Quelle, F. W., & Quelle, D. E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1258-1271.2005 · Cited by 292
Oncogenic ras and p53 Cooperate To Induce Cellular Senescence
Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., & Lowe, S. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3497-3508.2002 · Cited by 290
Buschmann, T., Potapova, O., Bar-Shira, A., Ivanov, V. N., Fuchs, S. Y., Henderson, S., Fried, V. A., Minamoto, T., Alarcon-Vargas, D., Pincus, M. R., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.8.2743-2754.2001 · Cited by 289
D’Amours, D., Sallmann, F. R., Dixit, V. M., & Poirier, G. G. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.20.3771 · Cited by 286
Control of the cell cycle and apoptosis
Weinberg, R. A., & Lundberg, A. S. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00046-5 · Cited by 285
Expression of p53 and Prognosis in Children with Malignant Gliomas
Pollack, I. F., Finkelstein, S. D., Woods, J., Burnham, J., Holmes, E. J., Hamilton, R. L., Yates, A. J., Boyett, J. M., Finlay, J. L., & Sposto, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012224 · Cited by 281
Pham, T. D., MacLennan, N. K., Chiu, C. T., Laksana, G. S., Hsu, J. L., & Lane, R. H. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00201.2003 · Cited by 279
Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2782-2790.2006 · Cited by 277
Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex
Weber, J. D., Kuo, M.-L., Bothner, B., DiGiammarino, E. L., Kriwacki, R. W., Roussel, M. F., & Sherr, C. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2517-2528.2000 · Cited by 275
Mitochondria and Reactive Oxygen Species: Physiology and Pathophysiology
Bolisetty, S., & Jaimes, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14036306 · Cited by 273
ATM: A mediator of multiple responses to genotoxic stress
Rotman, G., & Shiloh, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1203124 · Cited by 272
Maclean, K. H., Dorsey, F. C., Cleveland, J. L., & Kastan, M. B. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33700 · Cited by 272
Self-citationAlterations in the apoptotic machinery and their potential role in anticancer drug resistance
Kaufmann, S. H., & Vaux, D. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206945 · Cited by 265
TP53 and gastric carcinoma: A review
Fenoglio-Preiser, C. M., Wang, J., Stemmermann, G. N., & Noffsinger, A. (2003) · Human Mutation · doi:10.1002/humu.10180 · Cited by 252
p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage
Chao, C. (2000) · The EMBO Journal · doi:10.1093/emboj/19.18.4967 · Cited by 252
Midgley, C. A., Desterro, J. M., Saville, M. K., Howard, S., Sparks, A., Hay, R. T., & Lane, D. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203593 · Cited by 252
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation
Jin, Y., Lee, H., Zeng, S. X., Dai, M., & Lu, H. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg600 · Cited by 206
Pantoja, C., & Serrano, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202880 · Cited by 201
Webley, K., Bond, J. A., Jones, C. J., Blaydes, J. P., Craig, A., Hupp, T., & Wynford-Thomas, D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2803-2808.2000 · Cited by 192
Does p53 affect organismal aging?
Donehower, L. A. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10104 · Cited by 155
The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213159200 · Cited by 154
Ferrón, S., Mira, H., Franco, S., Cano-Jaimez, M., Bellmunt, E., Ramírez, C., Fariñas, I., & Blasco, M. A. (2004) · Development · doi:10.1242/dev.01215 · Cited by 152
Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer
Yamamoto, Y., Ibusuki, M., Okumura, Y., Kawasoe, T., Kai, K., Iyama, K., & Iwase, H. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9742-1 · Cited by 151
“p53 promotes many types of factors that are induced by cellular response to diverse stimuli such as DNA damage and hypoxia [32].”
p53 accumulates but is functionally impaired when DNA synthesis is blocked
Gottifredi, V., Shieh, S.-Y., Taya, Y., & Prives, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1036 · Cited by 147
Chen, J., & Kastan, M. B. (2010) · Genes & Development · doi:10.1101/gad.1968910 · Cited by 127
Self-citationDefective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23
MacPherson, D., Kim, J., Kim, T., Rhee, B. K., van Oostrom, C. T., DiTullio, R. A., Venere, M., Halazonetis, T. D., Bronson, R., de Vries, A., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600363 · Cited by 124
“The p53 tumor suppressor becomes stabilized and activated in response to diverse cellular stresses such as DNA damage, hypoxia, ribonucleotide depletion and oncogene activation (reviewed in Levine, 1997; Giaccia and Kastan, 1998).”
Backgroundp130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53
Taylor, W. R., Schönthal, A. H., Galante, J., & Stark, G. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005101200 · Cited by 110
Vogt Sionov, R., Coen, S., Goldberg, Z., Berger, M., Bercovich, B., Ben-Neriah, Y., Ciechanover, A., & Haupt, Y. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5869-5878.2001 · Cited by 94
Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export
Shinozaki, T., Nota, A., Taya, Y., & Okamoto, K. (2003) · Oncogene · doi:10.1038/sj.onc.1207176 · Cited by 93
“Although phosphorylation of p53 is important for regulation of p53 function (Giaccia and Kastan, 1998), it does not fully explain how p53 is activated after DNA damage (Ashcroft et al., 2000).”
BackgroundTong, X., O'Kelly, J., Xie, D., Mori, A., Lemp, N., McKenna, R., Miller, C. W., & Koeffler, H. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207628 · Cited by 86
“Numerous stress signals including DNA damage and chromosomal alterations (Giaccia and Kastan, 1998; Prives, 1998; Ashcroft et al., 2000), as well as aberrant expression of oncogenes, such ras and cmyc (Roy et al., 1994; Serrano et al., 1997; Zindy et al., 1998), are able to cause the activation and…”
BackgroundRetractedDecreased p21 levels are required for efficient restart of DNA synthesis after S phase block
Gottifredi, V., McKinney, K., Poyurovsky, M. V., & Prives, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310373200 · Cited by 76
LET-dependent survival of irradiated normal human fibroblasts and their descendents
Hamada, N., Funayama, T., Wada, S., Sakashita, T., Kakizaki, T., Ni, M., & Kobayashi, Y. (2006) · Radiation Research · doi:10.1667/rr3579.1 · Cited by 75
p53CSV, a Novel p53-Inducible Gene Involved in the p53-Dependent Cell-Survival Pathway
Park, W.-R., & Nakamura, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3339 · Cited by 72
Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69
“As such, the tight regulation of p53, at basal levels and in response to stress, is critical for p53 to exert its function when necessary [15,16].”
BackgroundKihara-Negishi, F., Yamamoto, H., Suzuki, M., Yamada, T., Sakurai, T., Tamura, T., & Oikawa, T. (2001) · Oncogene · doi:10.1038/sj.onc.1204756 · Cited by 69
Reagan-Shaw, S., Breur, J., & Ahmad, N. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0250 · Cited by 64
Seo, Y. R., & Jung, H. J. (2004) · Experimental & Molecular Medicine · doi:10.1038/emm.2004.64 · Cited by 56
Effective Active Ingredients Obtained through Biotechnology
Zappelli, C., Barbulova, A., Apone, F., & Colucci, G. (2016) · Cosmetics · doi:10.3390/cosmetics3040039 · Cited by 50
“P53 is well known to accumulate following various types of environmental stresses, including DNA-damaging agents, decreased oxygen, and heat shock, and redox stress [11].”
BackgroundMaya, R., & Oren, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203658 · Cited by 41
“The p53 protein is extensively regulated by phosphorylation on multiple sites (reviewed in Fuchs et al., 1998; Giaccia & Kastan 1998; Meek, 1998).”
BackgroundYOSHIKAWA, N., KAJIYAMA, H., NAKAMURA, K., UTSUMI, F., NIIMI, K., MITSUI, H., SEKIYA, R., SUZUKI, S., SHIBATA, K., CALLEN, D., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.4653 · Cited by 40
Reassessing the role of p53 in cancer and ageing from an evolutionary perspective
Aranda-Anzaldo, A., & Dent, M. A. R. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.01.001 · Cited by 36
Pare, R., Soon, P. S., Shah, A., & Lee, C. S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214604 · Cited by 23
Metadata
- Authors
- Giaccia, A. J., & Kastan, M. B.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1998-10-01
- Volume
- 12
- Issue
- 19
- Pages
- 2973-2983
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2156299289
- Cited by
- 1,314
- References
- 113
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.